Praxis Precision Medicines, Inc.
NASDAQ:PRAXBiotechnology
+$12.13 today
- Market cap
- $8.53B
- Beta
- 2.75
- P/E (TTM)
- -25.0
- EPS (TTM)
- -$11.31
Volume 0.43M
Average 0.45M
PRAX Common Stock Issued
Cash raised by issuing new shares.
Praxis Precision Medicines, Inc.NASDAQ: PRAX
Common Stock Issued · Q3 FY2026 · quarter ended Sep 2026
Common stock issued dips below year-ago levels
Q3 FY2026 common stock issued of $1.42M fell 79.1% year over year, behind the +509.2% change in trailing-twelve-month common stock issued. Over 3 fiscal years it compounded at +319.2% a year.
Context
- Common stock issued increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -79.1% toward the trailing-twelve-month pace of +509.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 704.26M USD
- Year-over-year change
- +37.6%
- 4-year CAGR
- +60.7%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 704.26M | +37.6% |
| FY2024 | 2024-12-31 | 512M | +459.0% |
| FY2023 | 2023-12-31 | 91.59M | +858.0% |
| FY2022 | 2022-12-31 | 9.56M | -91.0% |
| FY2021 | 2021-12-31 | 105.71M | — |
Common Stock Issued vs competitors
How PRAX compares with its peers on the latest reported figures
- PRAX's LTM Sep 2026 common stock issued of $1.24B is the largest of the 10 companies compared; the peer median is $117.67M.
- Its year-over-year change of +509.2% is the 3rd highest of 10, against a peer median of +154.8%.
- Over three fiscal years its annual growth of +319.2% compares with a peer median of +14.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.24B | +509.2% | +319.2% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $271.53M | +72.2% | +104.2% | 1357.6% |
| LTM Jun 2026 | $226.8M | +1490.1% | -12.7% | 6293.0% | |
| LTM Sep 2026 | $171M | +67.5% | +42.5% | 4.6% | |
| LTM Sep 2026 | $119.47M | +660.2% | -25.0% | — | |
| LTM Jun 2026 | $117.67M | +26.6% | -19.7% | 15.2% | |
| LTM Jun 2026 | $51.05M | +154.8% | +82.6% | 4.5% | |
| LTM Jun 2026 | $50.09M | +219.9% | +44.7% | 6.0% | |
| LTM Dec 2025 | $47.76M | +292.1% | -18.0% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $11.15M | -31.8% | — | — |
| Peer median (excluding PRAX) | $117.67M | +154.8% | +14.9% | 10.6% | |
Competitors are the stored peer set for PRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (167.06M) | (214.03M) | (123.28M) | (182.82M) | (303.27M) |
| Depreciation & Amortization | 182K | 419K | 432K | 358K | 140K |
| Deferred Income Tax | 2.09M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 22.69M | 28.59M | 24.86M | 41.36M | 33.94M |
| Change in Working Capital | 16.13M | (1.78M) | (13.03M) | 10.92M | 22.68M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 7.27M | 3.89M | (8.86M) | 6.71M | 12.1M |
| Other Working Capital | 8.87M | (5.67M) | (4.17M) | 4.21M | 10.58M |
| Other Non-Cash Items | 1.41M | 1.76M | (121K) | (1.58M) | (2.56M) |
| Operating Cash Flow | (124.55M) | (185.04M) | (111.14M) | (131.76M) | (249.07M) |
| Capital Expenditures | (1.05M) | (444K) | (50K) | 0 | (56K) |
| Acquisitions (Net) | 139.47M | (97.33M) | 0 | 0 | 0 |
| Purchases of Investments | (164.17M) | (83.02M) | 0 | (371.52M) | (623.81M) |
| Sales of Investments | 24.7M | 180.36M | 39M | 123.03M | 312.72M |
| Other Investing Activities | (139.47M) | 97.33M | 0 | 0 | 0 |
| Investing Cash Flow | (140.52M) | 96.89M | 38.95M | (248.49M) | (311.15M) |
| Debt Repayment | (763K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 105.71M | 9.56M | 91.59M | 512M | 704.26M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.64M | 904K | 279K | 2.33M | (2.09M) |
| Financing Cash Flow | 107.59M | 10.47M | 91.87M | 514.32M | 702.17M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (157.49M) | (77.69M) | 19.69M | 134.07M | 141.96M |
| Free Cash Flow | (125.6M) | (185.49M) | (111.19M) | (131.76M) | (249.12M) |
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
Intrinsic Alpha fair value
Locked
Current Price
$305.19
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.